| 425 | 48 | 100 |
| 下载次数 | 被引频次 | 阅读次数 |
目的观察西格列汀联合二甲双胍对2型糖尿病患者胰岛素抵抗、血脂和血压等心血管危险因素的影响。方法选择病史在5年以内的2型糖尿病患者60例,随机分为3组:西格列汀(A)组、二甲双胍(B)组、二甲双胍+西格列汀(C)组。服药前和服药后12周分别检测患者体重、身高、空腹血糖(FBG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、胆固醇(TCH)、低密度脂蛋白(LDL-C)、收缩压(SBP)、舒张压(DBP),并计算其体重指数(BMI)、胰岛素抵抗指数(HOMA-IR)。结果①各组用药前比较,FBG、HbA1c、BMI、TG、TCH、LDL-C、SBP、DBP均下降(P<0.05)。C组HOMA-IR用药前后比较差异有统计学意义(P<0.05)。②用药后,A组与C组及B组与C组FBG、HbA1c、TG、TCH、LDL-C、SBP、DBP比较差异均有统计学意义(P<0.05);A组与B组及A组与C组BMI比较差异有统计学意义(P<0.05),B组与C组BMI比较差异无统计学意义;用药后3组HOMA-IR组间比较差异无统计学意义。结论西格列汀、二甲双胍对降低血糖、调节血脂、控制血压、减轻胰岛素抵抗均有作用。二者联合用药后其降糖、调脂、降压、减轻胰岛素抵抗作用较单独用药效果更好。
Abstract:Objective To assess the effects of sitagliptin and metformin on insulin resistance,blood lipid and blood pressure in patients with type 2 diabetes mellitus( T2DM). Methods 60 patients with T2DM,a history of less than 5 years,were randomly divided into three groups: the sitagliptin group( A),the metformin group( B), the metformin + sitagliptin group( C). Before taking into the measurement,patients should be tested in weight, height,fasting blood glucose,fasting insulin,HbA1c,TG,TCH,LDL-C,SBP,DBP,and calculating body mass index( BMI),the insulin resistance index( HOMA-IR). After 12 weeks of medication,all the data were retested. Results ① After treatment compared with before,FBG,HbA1c,BMI,TG,TCH,LDL-C,SBP,DBP decreased( P <0. 05). There was statistically significant difference between pre-therapy and post-treatment in group C. ② Group A compared with group C,group B compared with group C,the levels of FBG,HbA1c,TG,TCH,LDL-C, SBP,DBP were statistically significant( P < 0. 05). Group A and group B were not statistically significant. There was no statistical significance between the three groups in BMI and HOMA-IR. Conclusion Sitagliptin and metformin have the effects in lowing glucose,improving lipids,reducing insulin resistance,and combination therapy is better than single drug effect.
[1]Sivertsen J,Rosenmeier J,Holst J J,et al.The effect of glucagon-like peptide1 on cardio-vascular risk[J].Nat Rev Cardiol,2012,9(4):209-22.
[2]Mu J,Woods J,Zhou Y P,et al.Chronic inhibition of dipeptidy peptidase-4 with a sitagliptin analog preserves pancreaticβ-cell mass and function in a rodent model of type 2 diabetes[J].Diabetes,2006,55(6):1695-1704.
[3]Flock C,Baggio L L,Longuet C,et al.Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulin otropic polypeptide are essential for the sustained metabolication of vildagliptin in mice[J].J Diabetes,2007,56(4):3006-13.
[4]Monami M,Lacomellil,Marchionni N,et al.Dipeptydil peptidase-4 inhibitors in type 2 diabetes:ameta-analysis of randomized clinical trials[J].Nutr Metab Cardiovase Dis,2010,20(4):224-35.
[5]Jendle J,Nauck M A,Matthews D R,et al.Weight loss with liraglutide,a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin,is primarily as a result of a reduction in fat tissue[J].Diabetes Obes Metab,2009,11(12):1163-72.
[6]Charbonnel B,Karasik A,Liu J,et al.Efficacy and safety of the dipeptidy peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone[J].Diabetes Care,2006,29(12):2638-43.
[7]沈晓霞,李光伟.DPP-4抑制剂的多中心临床试验研究进展[J].药品评价,2009,6(1):24-5.
[8]Buse J B,Polonsky K S,Burant C F,et al.Type 2 diabetes mellitus in 2010:individualizing treatment targets in diabetes care[J].Nat Rev Endocrinol,2011,7(2):67-8.
[9]Tremblay A J,Lamarche B,Lemelin N,et al.Effect of sitagliptin therapy on postprandial lipoprotein level in patient with type 2 diabetes[J].Diabetes Obes Metab,2011,13(4):366-73.
基本信息:
DOI:10.19405/j.cnki.issn1000-1492.2014.01.027
中图分类号:R587.1
引用信息:
[1]吕珊珊,潘天荣,钟兴,等.西格列汀联合二甲双胍对2型糖尿病患者胰岛素抵抗、血脂和血压的影响[J].安徽医科大学学报,2014,49(01):107-109.DOI:10.19405/j.cnki.issn1000-1492.2014.01.027.
基金信息:
安徽医科大学校科研基金(编号:2011xkj055)
2014-01-23
2014-01-23